JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet (NYSE:ZBH) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $117.00 to $120.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 13.81% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Royal Bank Of Canada raised their target price on shares of Zimmer Biomet from $110.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday. Sanford C. Bernstein increased their price objective on shares of Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a report on Thursday. Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Finally, Barclays upgraded Zimmer Biomet to a “hold” rating in a research report on Wednesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $111.95.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded down $1.41 during trading on Thursday, hitting $105.44. The company had a trading volume of 2,660,421 shares, compared to its average volume of 2,021,390. The stock has a 50 day simple moving average of $95.13 and a 200 day simple moving average of $92.08. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $112.54. The firm has a market capitalization of $20.11 billion, a P/E ratio of 26.69, a price-to-earnings-growth ratio of 2.34 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.90 EPS. As a group, analysts anticipate that Zimmer Biomet will post 8.55 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently modified their holdings of ZBH. BlackRock Inc. purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $1,344,282,000. State Street Corp increased its position in Zimmer Biomet by 0.6% during the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new position in Zimmer Biomet during the 2nd quarter valued at about $328,578,000. Dimensional Fund Advisors LP increased its position in Zimmer Biomet by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after buying an additional 24,208 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Zimmer Biomet in the second quarter valued at about $187,480,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q3 results beat expectations. Zimmer Biomet reported adjusted EPS of $1.90 versus the $1.88 consensus and revenue of $2.06 billion versus $2.04 billion expected. Revenue increased 3.1% year over year, providing a fundamental tailwind. Third-quarter earnings results
• Positive Sentiment: Analysts raised price targets. UBS lifted its target to $130 and kept a Buy rating; RBC raised its target to $125 and maintained Outperform. JPMorgan, Citi, Wells Fargo, and Bernstein also increased targets, though their ratings are neutral or equivalent. The revisions suggest improved expectations, but analyst conviction is mixed. UBS rating and target RBC rating and target
• Positive Sentiment: New surgical technology initiative. The company introduced “surgeon-guided autonomy,” a closed-loop framework called “Predict. Perform. Recover.” It could support Zimmer Biomet’s longer-term competitive positioning, though the announcement did not provide a near-term financial impact. Surgeon-guided autonomy announcement
• Neutral Sentiment: Shares recently reached a one-year high after the earnings beat. That reflects positive momentum, but could also leave the stock susceptible to consolidation. The available reports do not point to a specific new negative fundamental catalyst. Zimmer Biomet reaches one-year high

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.